DR. SACHIN KUMAR

                                                                                                                

SACHIN KUMAR  

Personal Details 

Date of Birth              2^nd May, 1982

Address                      Room No. 401, 4^th Floor, Dept. of Medical Oncology, Dr. BRA Institute Rotary Cancer Hospital, AIIMS, New Delhi-110029

Tel. No.                       +91-11-29575401 (Office)

E-mail                          This email address is being protected from spambots. You need JavaScript enabled to view it. ; This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Educational Qualifications 

Degree	Institute/University/College	Specialization / Subject	Year(s)
PhD	Dept. of Medicine, All India Institute of Medical Sciences, New Delhi, India	Title: Clinical Implications of Circulating DNA and Protein Markers in Lung Cancer   Chief Guide: Prof. (Dr.) Randeep Guleria	July 2005 - June 2010
MSc	Maharshi Dayanand University, Rohtak, Haryana, India	Biotechnology	2002-2004
BSc	Vaish PG College, Bhiwani, Haryana, India	Zoology, Botany, Chemistry	1999-2002

 

Academic / Research Experience 

Designation	Institute/University	Duration	Role
Scientist II	Dept. of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India	16th Sept. 2016 - till date	Research and patient care services
Assistant Professor	Amity Institute of Biotechnology & Amity Institute of Molecular Medicine & Stem Cell Research, Amity University Uttar Pradesh (Noida), India	12th March 2012 - 15th Sept. 2016	Research and teaching
Postdoctoral Fellow	Dept. of Human & Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, USA	19th Oct. 2010 – 28th Jan. 2012	Research
Senior Research Fellow	National Institute of Cancer Prevention & Research (Formerly ICPO), Noida, Uttar Pradesh, India	5th May 2010 - 11th Oct. 2010	Research

 

Research Projects: Ongoing 

Sr. No.	Project	Funding agency	Grant amount	Duration     (From – To)	Role
1	Elucidating the role of circular RNA circLIFR in the pathogenesis of small cell lung cancer	SERB, DST, New Delhi	~ 41 lakhs	21/01/2022 – 20/01/2025	PI (Collaborator:  Dr. Ishaan Gupta, IIT-Delhi)
2	Elucidation of the role of long non-coding RNA-Ginir as a biomarker in lung tumorigenesis	DBT,    New Delhi	~89 lakhs	19/08/2021 – 18/08/2024	PI (Collaborator: Dr. Manas Santra, NCCS, Pune)
3	Global profiling of circular RNAs in small cell lung cancer: a pilot study	AIIMS, New Delhi	10 lakhs	29/10/2020 – 28/10/2022	PI

 

Completed 

Sr. No.	Project	Funding agency	Grant amount	Duration     (From – To)	Role
1	Identification of a dysregulated circulating miRNA signature in non-small cell lung cancer	SERB,   New Delhi	~23 lakhs	09/09/2014 – 08/12/2017	PI (Young Scientist Scheme)
2	Investigating the efficacy of microRNAs as molecular marker in cytogenetically normal pediatric acute myeloid leukemia	DBT,   New Delhi	~65 lakhs	06/02/2015 –05/08/2018	Project coordinator and PI (Co-PI: Dr. Sameer Bakhshi)
3	Elucidating the mechanism of regulation of PD-L1 expression in lung cancer – role of epigenetics and copy number alterations	AIIMS, New Delhi	10 lakhs	18/09/2017 –17/09/2019	PI
4	The clinical significance of HOTAIR and HOTAIRM1 long non-coding RNAs in pediatric acute myeloid leukemia	AIIMS, New Delhi	10 lakhs	30/08/2017 –29/08/2019	Co-investigator
5	Liquid Biopsy: An exploratory study on exosomes based diagnostics for lung cancer	AIIMS-IIT Delhi	20 lakhs	11/2018 –11/2020	Co-investigator
6	Clinical significance of cell-free DNA in intraoperative pleural lavage fluid and plasma in patients undergoing pulmonary metastasectomy	AIIMS, New Delhi	10 lakhs	09/2018 –09/2020	Co-investigator
7	Evaluation of regulation of programmed death-ligand 1 (PD-L1) expression by microRNA in lung cancer	ICMR,  New Delhi	~47 lakhs	16/08/2019 – 15/08/2022	PI
8	The clinical significance of UCA1 long non-coding RNA in pediatric acute myeloid leukemia	AIIMS, New Delhi	10 lakhs	29/10/2020 – 28/10/2022	Co-investigator

 

Publications[Total Citations: 1315; h-index: 16 (Stats from Google Scholar)] 

1. Singh S, Pathak A, Kumar S, Malik PS, Elangovan R. Rapid immunomagnetic co-capture assay for quantification of lung Cancer associated exosomes. Journal of Immunological Methods 2022; 508: 13324. IF: 2.287. https://doi.org/10.1016/j.jim.2022.113324 
2. Tyagi A, Singh S, Pandey V, Kumar S, Malik PS, Elangovan R. SNC-TIRS: Label-free single nanoparticle characterization system based on total internal reflection scattering signal. Particle & Particle Systems Characterization 2022 (In Press). IF: 3.467. https://doi.org/10.1002/ppsc.202200130 
3. Budhraja A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, Sumit M, Ray A, Arulselvi S, Mathur P, Nambirajan A, Kumar S, Gupta R, Wig N, Trikha A, Guleria R, Sarkar C, Gupta I, Jain D. Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality. Dis Model Mech. 2022; 15(5):dmm049572. Citation: 1; IF: 5.732.                                            doi: 10.1242/dmm.049572
4. Kumar S*, Saikia J, Sharawat SK, Malik PS, Kumar S, Mohan A. Analysis of miR-375-3p, miR-197-3p, and miR-15a-5p expression and their clinical relevance as biomarkers in lung cancer. Technol Cancer Res Treat. 2022; 21:1-11. Citation: 1; IF: 2.876. https://doi.org/10.1177%2F15330338221080981
5. Kumar S*, Pandey M, Mir IA, Mukhopadhyay A, Sharawat SK, Jain D, Saikia J, Malik PS, Kumar S, Mohan A. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients. Human Cell 2022; 35(1):286-298.         IF: 4.374. https://doi.org/10.1007/s13577-021-00647-4
6. Pandey M, Mukhopadhyay A, Sharawat SK, Kumar S*. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer. Biochim Biophys Acta Rev Cancer 2021; 1876(1):188552. Citation: 15; IF: 11.414. https://doi.org/10.1016/j.bbcan.2021.188552.
7. Aftab M, Poojary SS, Seshan V, Kumar S, Agarwal P, Tandon S, Zutschi V, Das BC. Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer. Sci Rep 2021; 11:10323. Citation: 22; IF: 4.996. https://doi.org/10.1038/s41598-021-89388-w.
8. Kumari S, Arora M, Singh J, Chauhan SS, Kumar S, Chopra A. L-Selectin expression is associated with inflammatory microenvironment and favourable prognosis in breast cancer. 3Biotech 2021; 11:38. Citation: 4; IF: 2.893. https://doi.org/10.1007/s13205-020-02549-y.
9. Kumar S*, Pandey M, Sharawat SK. Biological functions of long noncoding RNAs and circular RNAs in small-cell lung cancer. Epigenomics 2020; 12(19):1751-1763. Citation: 4; IF: 4.357. https://doi.org/10.2217/epi-2020-0214.
10. Gaur V, Chaudhary S, Agarwal S, Sharawat SK, Bakhshi S, Sharma P, Kumar S*. miR-4772-5p and miR-196b as potential prognostic biomarker in pediatric core binding factor acute myeloid leukemia. Int J Med Res Health Sci 2020; 9(12):104-115. IF: 0.11
11. Kumar S*, Sharawat SK, Ali A, Gaur V, Malik PS, Pandey M, Kumar S, Mohan A, Guleria R. Differential expression of circulating serum miR-1249-3p, miR-3195 and miR-3692-3p in non-small cell lung cancer. Human Cell 2020; 33:839-849. Citation: 11; IF: 4.374. 10.1007/s13577-020-00351-9.
12. Kumar S*, Sharawat SK, Ali A, Gaur V, Malik PS, Kumar S, Mohan A, Guleria R. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr Probl Cancer 2020; 44(4): 100540. Citation: 35; IF: 2.367. https://doi.org/10.1016/j.currproblcancer.2020.100540
13. Gaur V, Chaudhary S, Tyagi A, Agarwal S, Sharawat SK, Sarkar S, Singh H, Bakhshi S, Sharma P, Kumar S*. Dysregulation of miRNA expression and their prognostic significance in pediatric cytogenetically normal acute myeloid leukemia. British J of Hematology 2020; 188(6): e90-e94.  Citation: 4; IF: 8.615. https://doi.org/10.1111/bjh.16375 
14. Bhat AA, Younes SM, Raza SS, Zarif L, Nisar S, Ahmed I, Mir R, Kumar S, Sharawat SK, Hashem S, Elfaki I, Kulinski M, KuttiKrishnan, S, Prabhu KS, Khan AQ, Yadav SK, El-Rifai W, Zargar MA, Zayed H, Haris M, Uddin S. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Mol Cancer 2020; 19(1): 57. Citation: 55; IF: 41.444. https://doi.org/10.1186/s12943-020-01175-9
15. Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019; 10(42): 4262-4275. Citation: 16; IF: 5.168. https://doi.org/10.18632/oncotarget.27008
16. Khurana S, Kumar S, Guleria R, Choudhury S, Gaur V, Saha B, Bose S. Molecular signatures of microRNA in obesity associated obstructive sleep apnea in middle-aged adults. Int J Med Res Health Sci 2019; 8(11): 57-66. IF: 0.11
17. Khurana S, Sharda S, Saha B, Kumar S, Guleria R, Bose S. Canvassing the etiology, prognosis and molecular signatures of obstructive sleep apnea. Biomarkers 2019; 24:1-16. Citation: 8; IF: 2.663. https://doi.org/10.1080/1354750X.2018.1514655
18. Kumar S*, Sharawat SK. Epigenetic regulators of programmed death-ligand 1 expression in human cancers. Translational Research 2018; 202:129-145. Citation: 30; IF: 10.171. https://doi.org/10.1016/j.trsl.2018.05.011. 
19. Kumar S*, Gaur V, Khurana S, Bose S, Kiran M, Sharawat SK. Proteomics – An update on recent tools and techniques. EC Proteomics and Bioinformatics 2018 February 8; 2(2):57-73.
20. Ali A, Kumar S, Kakaria VK, Mohan A, Luthra K, Upadhyay AD, Guleria R. Detection of promoter DNA methylation of APC, DAPK, and GSTP1 genes in tissue biopsy and matched serum of advanced stage lung cancer patients. Cancer Invest 2017; 35(6):423-430. Citation: 6; IF: 2.368. https://doi.org/10.1080/07357907.2017.1309547
21. Kumar S*, Bakhshi S. The diagnostic and prognostic role of microRNAs in pediatric acute myeloid leukemia – a review. Indian Journal of Medical Research 2016; 144(6):807-814.Citation: 2; IF: 5.274. 10.4103/ijmr.IJMR_220_15
22. Singh DK, Bose S, Kumar S*. Role of microRNA in regulating cell signaling pathways, cell cycle, and apoptosis in non-small cell lung cancer. Curr Mol Med 2016; 16(5): 474-486. Citation: 14; IF: 2.616. 10.2174/1566524016666160429120702
23. Singh DK, Bose S, Kumar S*. Regulation of expression of microRNAs by DNA methylation in lung cancer. Biomarkers 2016; 21(7):589-599. Citation: 15; IF: 2.663. https://doi.org/10.3109/1354750X.2016.1171906
24. Bose S, Ganguly S, Kumar S, Bookckfer FR. A Pit-1 binding site adjacent to E-Box 133 in the rat PRL promoter is necessary for pulsatile gene expression activity. Neurochem Res 2016; 41(6):1390-1400.Citation: 4; IF: 4.414. https://doi.org/10.1007/s11064-016-1843-y
25. Tilak AR, Kumar S, Pant MC, Mathur N, Kumar A. Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a north Indian population. DNA Cell Biol 2013; 32(2):66-72.Citation: 9; IF: 3.55. https://doi.org/10.1089/dna.2012.1792
26. Quinn BA, Dash R, Azab B, Sarkar, S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20(10):1397-1411. Citation: 229; IF: 6.498. https://doi.org/10.1517/13543784.2011.609167
27. Tilak AR, Kumar S, Jain M, Pant MC, Das BC, Guleria R, Mittal B, Mathur R, Kumar A. Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility. Cancer Invest 2011; 29(6):411-418. Citation: 29; IF: 2.368. https://doi.org/10.3109/07357907.2011.587070
28. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer. Cancer Invest 2011; 29(3):202-207. Citation: 29; IF: 2.368. https://doi.org/10.3109/07357907.2010.543208
29. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of circulating plasmaDNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 2010; 70(2):211-217. Citation: 55; IF: 6.081. https://doi.org/10.1016/j.lungcan.2010.01.021
30. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma DNA level inpredicting therapeutic efficacy in advanced non-small cell lung cancer. Eur Respir J 2010; 36(4):885-892. Citation: 49;              IF: 33.795. https://doi.org/10.1183/09031936.00187909
31. Kumar S, Guleria R, Singh V, Mohan A, Bharti AC, Das BC. Lack of utility of plasmaTNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer. Cytokine 2010; 51(3):245-248. Citation: 4; IF: 3.926. https://doi.org/10.1016/j.cyto.2010.05.007
32. Kumar S, Guleria R, Mohan A, Singh V, Ali A, Bharti AC, Das BC. Utility of plasmatumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma. Biomarkers 2010; 15 (5):446-453. Citation: 10; IF: 2.663. https://doi.org/10.3109/1354750X.2010.485699
33. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma nucleosome levelsmight predict response to therapy in patients with advanced non-small cell lung cancer. Clin Lung Cancer 2010; 11(1):36-44.Citation: 30; IF: 4.84.https://doi.org/10.3816/CLC.2010.n.006
34. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma vascularendothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer. BMC Cancer 2009; 9(1):421.Citation: 19; IF: 4.638. https://doi.org/10.1186/1471-2407-9-421
35. Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer Prev 2009; 10(3):335-338. Citation: 75; IF: 1.23; PMID: 19640168
36. Kumar S, Mohan A, Guleria R. Prognostic implications of circulating anti-p53 antibodies inlung cancer-a review. Eur J Cancer Care 2009; 18(3):248-254. Citation: 41; IF: 2.328. https://doi.org/10.1111/j.1365-2354.2008.01019.x
37. Mohan A, Singh P, Kumar S, Mohan C, Pathak AK, Pandey RM, Guleria R. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2008; 9(4):557-562. Citation: 66; IF: 1.23; PMID: 19256738
38. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006; 52(10):1833-1842. Citation: 274; IF: 12.167. https://doi.org/10.1373/clinchem.2005.062893
39. Kumar S, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection:present and future: a review. Biomarkers 2006; 11(5):385-405. Citation: 152; IF: 2.663.

https://doi.org/10.1080/13547500600775011

1. Kumar S, Singh V, Chandra S, e. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer 2009; 65(2):254. IF: 6.081 (Letter to Editor).

(* denotes articles published as a corresponding author) 

 

Abstracts 

1. Chitikela SD, Malik PS, Khurana S, Kumar S, Pushpam D, Mohan A, Jain D. Familial aggregation in non-small cell lung cancer - an observational study (EP03.01-006). J Thor Oncol 2022; 17(9):S239.
2. Saikia J, Malik PS, Kumar S, Jain D, Madam K, Bharati SJ, Deo S, Kumar S. Can cell-free DNA in pleural lavage serve as a predictive and prognostic biomarker among surgically treated non-small cell cancers of the lung (NSCLC): a pilot study. Lung Cancer 2022; 165 (S1): S2.
3. Saikia J, Malik PS, Kumar S, Jain D, Madam K, Bharati SJ, Deo S, Kumar S. Predictive and prognostic value of cell-free DNA in plasma and pleural lavage among surgically treated adenocarcinomas of the lung (ADCL). Annals of Oncology 2021; 32 (S6): S1348.
4. Kumar S, Sharawat SK, Ali A, Malik PS, Mohan A, Guleria R. Diagnostic and prognostic utility of differentially expressed circulating microRNAs in Indian NSCLC patients (EP1.03-20). J Thor Oncol 2019; 14 (10S): S960-S961.
5. Malik PS, Yadav A, Jain D, Pathy S, Mohan A, Khurana S, Kumar S. Pemetrexed-carboplatin versus paclitaxel (weekly)-carboplatin as first line chemotherapy in advanced non-squamous NSCLC (P1.01-02). J Thor Oncol 2019; 14 (10S): S354-355.
6. Verma S, Malik PS, Yadav A, Jain D, Khurana S, Kumar S. Thymidylate synthase and folate receptor alpha expression as potential biomarkers for efficacy of pemetrexed in NSCLC (EP1.01-71). J Thor Oncol 2019; 14 (10S): S939.
7. Gaur V, Chaudhary S, Tyagi A, Bakhshi S, Sharma P, Kumar S. Differential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML). Annals of Oncology 2019; 30 (Supplement 5): v50-v51.
8. Gaur V, Chaudhary S, Tyagi A, Bakhshi S, Sharma P, Kumar S. Dysregulated microRNA expression in pediatric cytogenetically normal acute myeloid leukemia patients (#1798). Proceedings of the American Association for Cancer Research 2019; 60:460-461.
9. Kumar S, Ali A, Guleria R. Identification of differentially expressed circulating miRNAs in the serum of NSCLC patients using next generation sequencing (P2.01-011). J Thor Oncol 2017; 12 (1S): S789-S790.
10. Ali A, Kumar S, Kakaria V, Mohan A, Luthra K, Upadhyay A, Guleria R. Detection of promoter DNA methylation of APC, DAPK, and GSTP1 genes in tissue biopsy and matched serum of advanced stage lung cancer patients (P2.01-007). J Thor Oncol 2017; 12 (1S): S787.
11. Guleria R, Mohan A, Kumar S, Ali A, Kumar A. Survival outcomes in advance non-small cell lung cancer – a developing country scenario (P4421). Eur Respir J 2011; 38 (Suppl. 55): 815S.
12. Das BC, Bharti AC, Mohan A, Guleria R, Kumar R, Kumar S. Vascular endothelial growth factor (VEGF) as a marker of response to therapy in lung cancer. Indian J Cancer 2008; 45 (suppl): S22.
13. Mohan A, Guleria R, Pathak AK, Kumar S, Pandey RM, Mohan C. Impact of symptoms, respiratory status, nutritional profile, and quality of life on response to chemotherapy in patients with advanced non small cell lung cancer. Chest 2007: 132 (4); S589A.

 

Awards / Honors 

• Second Prize for Oral Paper Presentation (Differential expression of miR-197-3p and miR-375-3p and their correlation with survival outcomes and response to therapy in lung cancer) in NALCCON 2021: 12^th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized on the virtual platform by JIPMER, Puducherry on 26-27 Nov. and 3-4 Dec. 2021.
• First Prize for Oral Paper Presentation (Analysis of the expression of PD-L1 and PD-L1 regulatory microRNAs in lung cancer) in NALCCON 2020: 10^th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized on the virtual platform by Max Institute of Cancer Care, Delhi/NCR on 26-27 Sept. and 3-4 Oct. 2020.
• Young Investigator Award for the best oral paper presentation (Evaluation of deregulated circulating microRNA expression in advanced stage NSCLC patients) in NALCCON 2019: 9^th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized at KGMU, Lucknow on 14-15 Dec. 2019.
• First Prize for Oral Paper Presentation (Evaluation of the expression and regulation of programmed death ligand-1 (PD-L1) in lung cancer) in NALCCON 2018: 8^th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized at AIIMS Patna on 6-7^th October, 2018.
• Second Prize for the Poster Presentation in International Symposium on "Frontiers in Cancer Research: Prevention to Therapeutics" held during November 15-16, 2013 at Amity University Uttar Pradesh.
• Elected Finance Secretary of Society of Young Scientists (SYS), AIIMS (2009-10).
• Third Prize in the International Competition on Article Writing: 2009 (Proteomics) organized by Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India.
• The Best Poster Award in RGCON 2009: 8^th International Conference on Lung and Esophageal Cancers held at Rajiv Gandhi Cancer Institute & Research Centre, Delhi.
• Special Appreciation Award in IACR (Indian Association for Cancer Research) essay competition 2009 on “Bioinformatics in Cancer Drug Design”.
• Citation Award in IACR (Indian Association for Cancer Research) essay competition 2007 for the best essay on “Cancer Stem Cells”.
• Qualified Junior Research Fellowship (JRF-NET) in life science, conducted by Council of Scientific and Industrial Research (CSIR) in June 2004.
• Qualified Junior Research Fellowship (JRF-NET) in life science, conducted by Council of Scientific and Industrial Research (CSIR) in December 2003.
• Qualified ICMR JRF examination conducted on July 11, 2004 as Junior Research Fellow in ICMR Funded Research Projects/Scheme.
• Merit certificate for standing second in the college in the university examination in B.Sc-3rd year from Vaish P.G. College, Bhiwani in April 2002.
• Merit certificate for standing first in the college in the university examination in B.Sc-2nd year from Vaish P.G. College, Bhiwani in April 2001.
• Distinction in matriculation examination conducted by Board of School Education Haryana in 1997.

 

Membership 

• Life Member of the Indian Society for Study of Lung Cancer (ISSLC)
• Life Member of the Indian Association for Cancer Research (IACR)
• Member of the Research and Education Society of Medical Oncology, AIIMS, New Delhi
• Associate Member of the Cancer Epigenetics Society

 

Teaching Experience 

Four and half years of teaching experience in subjects like Animal Biotechnology, Cancer Biology, Molecular

Cell Biology, Recombinant DNA Technology and Gene Therapy (at UG/PG/PhD level) 

 

Editorial Board Member 

1. Associate Editor (Cancer Section) of BMC Pulmonary Medicine (Springer Nature)

 

Journals / Grant Reviewer (Ad-hoc):

 

• Reviewed extramural research proposals submitted to SERB-DST for funding
• Reviewed ICMR fellowship reports